The Facioscapulohumeral Muscular Dystrophy (FSHD) drugs in development market research report provides comprehensive information on the therapeutics under development for Facioscapulohumeral Muscular Dystrophy (FSHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Facioscapulohumeral Muscular Dystrophy (FSHD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Facioscapulohumeral Muscular Dystrophy (FSHD) and features dormant and discontinued products.
GlobalData tracks 28 drugs in development for Facioscapulohumeral Muscular Dystrophy (FSHD) by 26 companies/universities/institutes. The top development phase for Facioscapulohumeral Muscular Dystrophy (FSHD) is preclinical with 17 drugs in that stage. The Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline has 23 drugs in development by companies and five by universities/ institutes. Some of the companies in the Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline products market are: Sanofi, F. Hoffmann-La Roche and Arrowhead Pharmaceuticals.
The key targets in the Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline products market include Double Homeobox Protein 4, AP2 Associated Protein Kinase 1, and Androgen Receptor.
The key mechanisms of action in the Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline product include Double Homeobox Protein 4 Inhibitor with 16 drugs in Phase II. The Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline products include five routes of administration with the top ROA being Oral and ten key molecule types in the Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline products market including Small Molecule, and Antisense Oligonucleotide.
Facioscapulohumeral Muscular Dystrophy (FSHD) overview
Facioscapulohumeral muscular dystrophy (FSHD) typically manifests with varying degrees of facial, scapular stabilizer, and dorsiflexor muscle weakness. Progression is slow, with about 20% of individuals eventually requiring a wheelchair, though life expectancy remains unaffected. Diagnosis of FSHD1 involves identifying a heterozygous pathogenic contraction of the D4Z4 repeat array on chromosome 4q35 with a chromosome 4 permissive haplotype. FSHD2 diagnosis is established by detecting D4Z4 repeat array hypomethylation on chromosome 4q35 with the same haplotype, linked to heterozygous pathogenic variants in SMCHD1 or DNMT3B. Treatment addresses symptoms, involving physical therapy, orthoses, surgery for scapular fixation, pain management, respiratory function monitoring, and specific interventions for ocular, auditory, and other associated issues.
For a complete picture of Facioscapulohumeral Muscular Dystrophy (FSHD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
